Treating Type I Diabetes Using a Therapy That Targets C-peptide

SLU ID 12-012 | GPR146 as a C-peptide receptor

Background

In diabetic models, C-peptide appears to counteract the deleterious effects of insulin in several tissues, including the kidneys and the vasculature. This suggests that C-peptide may represent a novel threapeutic for treating diabetes-assoicated diseases.

Overview

Researchers at Saint Louis University have demonstrated that the orphan G protein coupled receptor, GPR146, is a likely candidate for the C-peptide receptor. This potentially enables the design of C-peptide agonists and sensitizers.

Benefits

The potential benefits of this technology include:

• Increasing the potential treatments for diabetes-associated diseases and complications

• Increasing the experimental models available for studying diabetes-associated complications

Applications

The potential applications of this technology include treating various diabetes-associated diseases such as:

• peripheral vascular disease

• diabetic nephropathy

Opportunity

Saint Louis University is seeking a partner to further develop and commercialize this technology.